News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
385,510 Results
Type
Article (33576)
Company Profile (64)
Press Release (351870)
Multimedia
Podcasts (65)
Webinars (6)
Section
Business (102571)
Career Advice (2561)
Deals (18534)
Drug Delivery (94)
Drug Development (50253)
Employer Resources (154)
FDA (9468)
Job Trends (9610)
News (184476)
Policy (19495)
Tag
Academia (2111)
Accelerated approval (3)
Adcomms (20)
Allergies (63)
Alliances (25703)
ALS (67)
Alzheimer's disease (989)
Antibody-drug conjugate (ADC) (101)
Approvals (9468)
Artificial intelligence (165)
Autoimmune disease (13)
Automation (7)
Bankruptcy (135)
Best Places to Work (7866)
BIOSECURE Act (9)
Biosimilars (72)
Biotechnology (45)
Bladder cancer (46)
Brain cancer (23)
Breast cancer (214)
Cancer (1524)
Cardiovascular disease (133)
Career advice (2157)
Career pathing (31)
CAR-T (121)
Cell therapy (291)
Cervical cancer (14)
Clinical research (40730)
Collaboration (476)
Compensation (327)
Complete response letters (17)
COVID-19 (2101)
CRISPR (36)
C-suite (109)
Cystic fibrosis (64)
Data (1544)
Decentralized trials (1)
Denatured (6)
Depression (39)
Diabetes (204)
Diagnostics (3780)
Digital health (13)
Diversity (4)
Diversity, equity & inclusion (40)
Drug discovery (79)
Drug pricing (85)
Drug shortages (22)
Duchenne muscular dystrophy (68)
Earnings (48403)
Editorial (41)
Employer branding (18)
Employer resources (134)
Events (58982)
Executive appointments (319)
FDA (10263)
Friedreich's ataxia (4)
Frontotemporal dementia (7)
Funding (406)
Gene editing (84)
Generative AI (17)
Gene therapy (255)
GLP-1 (532)
Government (3393)
Grass and pollen (2)
Guidances (39)
Healthcare (12224)
Huntington's disease (15)
IgA nephropathy (20)
Immunology and inflammation (81)
Indications (21)
Infectious disease (2209)
Inflammatory bowel disease (87)
Inflation Reduction Act (7)
Influenza (39)
Intellectual property (43)
Interviews (463)
IPO (9292)
IRA (38)
Job creations (2079)
Job search strategy (1777)
Kidney cancer (8)
Labor market (24)
Layoffs (359)
Leadership (24)
Legal (4244)
Liver cancer (47)
Lung cancer (229)
Lymphoma (121)
Machine learning (6)
Management (53)
Manufacturing (190)
MASH (61)
Medical device (7634)
Medtech (7635)
Mergers & acquisitions (9580)
Metabolic disorders (536)
Multiple sclerosis (63)
NASH (21)
Neurodegenerative disease (66)
Neuropsychiatric disorders (23)
Neuroscience (1379)
NextGen: Class of 2025 (4331)
Non-profit (3358)
Now hiring (11)
Obesity (273)
Opinion (231)
Ovarian cancer (61)
Pain (55)
Pancreatic cancer (63)
Parkinson's disease (108)
Partnered (12)
Patents (115)
Patient recruitment (63)
Peanut (37)
People (22149)
Pharmaceutical (21)
Pharmacy benefit managers (12)
Phase I (11654)
Phase II (17712)
Phase III (15065)
Pipeline (809)
Policy (113)
Postmarket research (1695)
Preclinical (4896)
Press Release (34)
Prostate cancer (68)
Psychedelics (24)
Radiopharmaceuticals (126)
Rare diseases (300)
Real estate (3174)
Recruiting (64)
Regulatory (13345)
Reports (25)
Research institute (1743)
Resumes & cover letters (429)
Rett syndrome (5)
RNA editing (4)
RSV (37)
Schizophrenia (56)
Series A (68)
Series B (43)
Service/supplier (5)
Sickle cell disease (41)
Special edition (10)
Spinal muscular atrophy (125)
Sponsored (27)
Startups (1950)
State (1)
Stomach cancer (8)
Supply chain (37)
Tariffs (29)
The Weekly (57)
Vaccines (554)
Venture capitalists (32)
Weight loss (203)
Women's health (18)
Worklife (20)
Date
Today (22)
Last 7 days (566)
Last 30 days (1597)
Last 365 days (19946)
2025 (6646)
2024 (21124)
2023 (23711)
2022 (30573)
2021 (34411)
2020 (33020)
2019 (29322)
2018 (22556)
2017 (18893)
2016 (18895)
2015 (21432)
2014 (15556)
2013 (12830)
2012 (13513)
2011 (14252)
2010 (12202)
Location
Africa (645)
Alabama (32)
Alaska (3)
Arizona (117)
Arkansas (8)
Asia (23249)
Australia (3944)
California (3580)
Canada (1281)
China (327)
Colorado (161)
Connecticut (167)
Delaware (110)
Europe (53278)
Florida (563)
Georgia (122)
Idaho (33)
Illinois (350)
India (12)
Indiana (201)
Iowa (3)
Japan (118)
Kansas (71)
Kentucky (13)
Louisiana (2)
Maine (26)
Maryland (531)
Massachusetts (2558)
Michigan (115)
Minnesota (200)
Mississippi (2)
Missouri (47)
Montana (10)
Nebraska (12)
Nevada (39)
New Hampshire (42)
New Jersey (1139)
New Mexico (11)
New York (1100)
North Carolina (603)
North Dakota (3)
Northern California (1553)
Ohio (101)
Oklahoma (6)
Oregon (17)
Pennsylvania (802)
Puerto Rico (8)
Rhode Island (22)
South America (908)
South Carolina (9)
South Dakota (1)
Southern California (1409)
Tennessee (60)
Texas (490)
United States (13571)
Utah (118)
Virginia (85)
Washington D.C. (34)
Washington State (270)
West Virginia (3)
Wisconsin (23)
385,510 Results for "one drop".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Autoimmune disease
Immunovant Will Drop One Myasthenia Gravis Asset, Continuing to Favor Another
Analysts were happy with batoclimab’s performance in the chronic autoimmune disorder, but Immunovant said it will continue to focus on another next-gen asset for the indication.
March 19, 2025
·
1 min read
·
Annalee Armstrong
Mergers & acquisitions
Novartis Drops up to $1.7B to Bolster Oligo Pipeline With Regulus Buy
At the heart of the acquisition is Regulus’ farabursen, an miRNA-targeting oligonucleotide in early-stage development for rare autosomal dominant polycystic kidney disease.
April 30, 2025
·
2 min read
·
Tristan Manalac
Weight loss
Pfizer Drops Lead Obesity Asset After Liver Safety Concerns, Overall Review
Pfizer’s discontinuation of danuglipron brings the company down to a single molecule in its obesity pipeline.
April 14, 2025
·
2 min read
·
Tristan Manalac
Weight loss
Kallyope Discreetly Drops Disappointing Data for Oral Obesity Candidate
While Kallyope’s drugs are mechanistically unique, the biotech is competing in a crowded space, with other therapies that appear to elicit superior weight-loss.
February 27, 2025
·
2 min read
·
Tristan Manalac
Compensation
Average Life Sciences Salaries Up 9% in 2024, but Bonuses and Equity Values Drop:
BioSpace
Report
The 9% average salary increase from 2023 to 2024 was the largest for life sciences professionals since 2021. Several factors could be behind the spike, including companies providing higher pay because bonuses and stock compensation went down.
March 25, 2025
·
3 min read
·
Angela Gabriel
Tariffs
Pharmas Bleed Value as Trump Tariffs Roil Global Markets
Billions in market cap are being shed as the markets reel over President Donald Trump’s escalating trade war. Eli Lilly’s value has dropped more than $95 billion in just one month.
April 9, 2025
·
1 min read
·
Annalee Armstrong
Press Releases
NexThera Completes First Patient Enrollment in U.S. Clinical Trial for ‘NT-101,’ an Eye Drop Treatment for Wet AMD
April 9, 2025
·
2 min read
Cardiovascular disease
Mineralys’ Hypertension Drug Drops Blood Pressure in Phase II/III, Setting Up Market Clash
Mineralys’ shares got a more than 50% boost Monday morning as new data showed its hypertension drug reduced blood pressure in a pair of clinical trials.
March 10, 2025
·
2 min read
·
Dan Samorodnitsky
Vaccines
Good Day for Gardasil as Merck Wins Safety Suit, Drops $1B for Manufacturing Push
According to Judge Kenneth Bell, there is a lack of evidence to conclude that Merck willingly misrepresented the safety of its HPV vaccine Gardasil to patients and prescribers.
March 12, 2025
·
2 min read
·
Tristan Manalac
Layoffs
Allakos Will Axe 75% of Workforce, Drop Hives Candidate
Following disappointing clinical trial results for AK006, Allakos will cut its workforce down to under 20 employees as it explores strategic alternatives.
January 27, 2025
·
1 min read
·
Angela Gabriel
1 of 38,551
Next
